Giant Cell Arteritis, Horton Disease
Conditions
Brief summary
Giant cell arteritis (GCA) or Horton's disease: frequent large vessel vasculitis (cephalic) (incidence estimated at 9 per 100,000 in France), potentially responsible for blindness. Treatment: corticosteroid therapy, which is effective in the vast majority of cases. Clinical problem: relapse; 36% to 44% of patients have a relapse that occurs in the first year for many patients, requiring a re-escalation of corticosteroid therapy, with its consequences: * Cumulative dose of corticosteroid therapy that causes cardiovascular and infectious morbidity. * Requires additional immunosuppressive treatment.
Interventions
OTHERno intervention
no intervention
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients aged 45 years or older * Patients with giant cell arteritis according to ACR criteria or revised criteria incorporating imaging parameters, * Patients managed at the University Hospital of Carémeau in Internal Medicine from 01/01/2011 to 01/01/2020.
Exclusion criteria
None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Clinical and paraclinical characteristics of patients diagnosed with ACG | day 1 | Describe the clinical and paraclinical characteristics of patients diagnosed with ACG to determine whether certain characteristics are significantly associated with a higher risk of developing corticosteroid dependence |
Countries
France
Outcome results
None listed